Innovation & intellectual property · 10/12/2014Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Interim Extension for Mepolizumab Patent
Summary
The U.S. Patent and Trademark Office has issued a one-year extension for the term of U.S. Patent No. 5,693,323, which covers the recombinant humanized monoclonal antibody (IgG1, Kappa)-mepolizumab, due to a request under 35 U.S.C. 156(d)(5).
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →